Wall Street analysts forecast that GoodRx Holdings, Inc. (GDRX) will report quarterly earnings of $0.09 per share in its upcoming release, pointing to a year-over-year increase of 12.5%. It is anticipated that revenues will amount to $199.81 million, exhibiting an increase of 1.6% compared to the year-ago quarter.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this p ...

Executive Changes - GoodRx Holdings CFO Karsten Voermann resigned effective January 16, citing personal reasons [1] - The resignation was not due to any disagreement with the company on operations, policies, or practices [2] - Chief Accounting Officer Romin Nabiey will serve as interim CFO while the company searches for a permanent successor [2] - Nabiey will also continue in his current roles as Chief Accounting Officer and Principal Accounting Officer [3] Financial Performance - GoodRx reported an 8% increase in revenue in Q3, driven by a 4% rise in prescription transactions revenue and a 7% increase in monthly active consumers [3] Strategic Initiatives - The company entered the over-the-counter market in October with a new eCommerce service, partnering with contraceptive maker Opill [5] - The eCommerce service is part of a broader strategy to integrate health and wellness brands into the platform, streamlining purchasing and increasing accessibility [5] - GoodRx and partner pharmacies began offering Affirm's pay-over-time option directly to consumers in October, allowing approved consumers to select Affirm for select medications at participating retailers [5] Leadership Vision - Interim CEO Scott Wagner emphasized the company's focus on medicine affordability and access, stating that this strategic approach has enabled GoodRx to gain market share and strengthen its value proposition [4]

Prescription fills for blockbuster weight loss drugs in the U.S. more than doubled in 2024, even with limited insurance coverage and high out-of-pocket costs for the treatments, according to data released Thursday by drug savings company GoodRx. The figures offer more evidence of the insatiable demand for a buzzy class of medications called GLP-1 and GIP agonists, which mimic gut hormones to suppress appetite and regulate blood sugar. That includes Novo Nordisk's weight loss drug Wegovy and Eli Lilly's obes ...

For the quarter ended September 2024, GoodRx Holdings, Inc. (GDRX) reported revenue of $195.25 million, up 8.5% over the same period last year. EPS came in at $0.08, compared to $0.06 in the year-ago quarter.The reported revenue represents a surprise of -0.05% over the Zacks Consensus Estimate of $195.35 million. With the consensus EPS estimate being $0.09, the EPS surprise was -11.11%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to ...

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -11.11%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.08, delivering a surprise of -11.11%.Over the last four quarters, the ...

The upcoming report from GoodRx Holdings, Inc. (GDRX) is expected to reveal quarterly earnings of $0.09 per share, indicating an increase of 50% compared to the year-ago period. Analysts forecast revenues of $195.35 million, representing an increase of 8.6% year over year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's ear ...

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of GoodRx Holdings, Inc. (NASDAQ: GDRX) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, GoodRx insiders caused the company to misrepresent or fail to disclose that (1) while Kroger accounted for less than 5% of the pharmacies accepting GoodRx discounts, Kroger was responsible for nearly 25% of GoodRx's total prescr ...

Author's note: I present and update my best small-cap Busted IPO stock ideas only to subscribers of my exclusive marketplace, The Busted IPO Forum . Try a free 2-week trial today by clicking on our logo below! It has been nearly two years since our initial look at GoodRx Holdings, Inc. (NASDAQ: GDRX ). We concluded that initial article on this 'Busted IPO' by saying the company was going through a lot of changes, the shares were worthy only The Busted IPO Forum is an investing group led by Bret Jensen, Chie ...

NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (NASDAQ: GDRX) on behalf of long-term stockholders following a class action complaint that was filed against GoodRx on April 22, 2024 with a Class Period from September 23, 2020, to November 8, 2022. Our investigation concerns whether the board of directors of GoodRx have breached their fiduciary duties to the company. ...

It was a mixed bag of growth and challenges for digital healthcare platform GoodRx during the second quarter. In reporting its second-quarter results Thursday (Aug. 8), GoodRx said monthly active users (MACs) rose 8%, contributing to a 7% rise in prescription transactions revenue, which totaled $146.7 million. While overall second-quarter revenue rose 6%, to $200.6 million, subscription revenue sank 8%, to $22 million, driven by a decrease in the number of subscription plans due to last month's sunsetting o ...